Ascentage's Bcl-xL Inhibitor Starts US Trials for Macular Edema

Ascentage Pharma reported its Bcl-xL inhibitor started a Phase I trial in the US to treat diabetic macular edema. The trial is being conducted by Unity Biotech (NSDQ: UBX), which in-licensed US rights to the candidate in 2016. In the future, Ascentage plans to establish a joint venture with Unity to develop and commercialize the candidate in China . Ascentage develops novel treatments for cancer, chronic hepatitis B and age-related diseases, focusing on protein-protein interactions. More details.... Stock Symbol: (HK: 6855) Share this with colleagues: // //